Drug Overview
Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions. Torisel works by binding to an intracellular protein, FKBP12, and the protein-drug complex inhibits the activity of mTOR. The inhibition of mTOR prevents the transcription of mRNAs and translation of proteins required for cell cycle progression from G1 to S phase.
Analyst Outlook
Torisel (temsirolimus; Pfizer) has been relatively successful in the renal cell carcinoma (RCC) market even though its sales have never reached those of Pfizer’s other RCC staples Inlyta (axitinib) and Sutent (sunitinib). Due to the lack of development of Torisel in combination with a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapy, it is forecast to lose patient share to a range of more efficacious combination therapies expected to be approved for the first-line treatment of RCC. Pfizer will aim to protect its share of first-line patients by promoting the use of Inlyta, which is being investigated in combination with both Bavencio (avelumab; Merck KGaA/Pfizer) and Keytruda (pembrolizumab; Merck & Co). Torisel is expected to experience significant generic erosion with key patents expiring in August 2019 (US), February 2020 (Japan), and March 2020 (EU), while Inlyta’s patents do not expire until 2025
Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions. Torisel works by binding to an intracellular protein, FKBP12, and the protein-drug complex inhibits the activity of mTOR. The inhibition of mTOR prevents the transcription of mRNAs and translation of proteins required for cell cycle progression from G1 to S phase.
Analyst Outlook
Torisel (temsirolimus; Pfizer) has been relatively successful in the renal cell carcinoma (RCC) market even though its sales have never reached those of Pfizer’s other RCC staples Inlyta (axitinib) and Sutent (sunitinib). Due to the lack of development of Torisel in combination with a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapy, it is forecast to lose patient share to a range of more efficacious combination therapies expected to be approved for the first-line treatment of RCC. Pfizer will aim to protect its share of first-line patients by promoting the use of Inlyta, which is being investigated in combination with both Bavencio (avelumab; Merck KGaA/Pfizer) and Keytruda (pembrolizumab; Merck & Co). Torisel is expected to experience significant generic erosion with key patents expiring in August 2019 (US), February 2020 (Japan), and March 2020 (EU), while Inlyta’s patents do not expire until 2025
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
